Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Large Middle Molecule and Albumin Removal: Why Should We Not Rest on Our Laurels?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Large uremic toxins: an unsolved problem in end-stage kidney disease - Wolley MJ and Hutchison CA.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Latest Trends in Hemodiafiltration.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Leptin Levels and Appetite Score in Patients on Hemodialysis Using High Flux or Medium Cutoff Membranes
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Long term effect of medium cut-off dialyzer on middle uremic toxins
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Long term evaluation of the expanded hemodialysis (HDx) on dialysis adequacy, anemia and quality of life
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Long-term effect of medium cut-off dialyzer on middle uremic toxins and cell-free hemoglobin - Cho N-J et al.
Visit resource site
PD
Longitudinal Experience with Remote Patient Monitoring for Automated Peritoneal Dialysis Patients - Milan Manani S, et. al.
Visit resource site
PD
Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription - Davies SJ, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
MCO HD removes a wide range of middle molecules more effectively than high-flux HD and even exceeds the performance of high-volume HDF for large solutes, particularly λFLC.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
MCO Membranes: Enhanced Selectivity in High-Flux Class
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
MCO Membranes: Enhanced Selectivity in High-Flux Class - Boschetti-de-Fierro A et al.
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.